Fig. 5: Selective inhibition of p300 prevents the progression of lung fibrosis by suppressing the production of chemokines and macrophage polarization.

a Representative MTS-stained lung sections from BLM-treated mice treated with control or C646. b The deposition of collagen was quantified in MTS-stained lung samples from BLM-treated mice treated with control or C646. n = 4–5 per group. c Immunohistochemical images of α-SMA protein in lung samples from BLM-treated mice treated with control or C646. d The α-SMA intensity/hematoxylin ratio was quantified using ImageJ software. n = 8–11 per group. e Flow cytometric analysis of M2 (CD45⁺/F4/80⁺/CD206⁺) cells in the lungs. n = 4–5 per group. f Quantification of the percentage of M2 macrophages. g ELISA analysis of CCL2, CCL7, and CCL12 protein levels in serum and BAL fluid from control or C646-treated mice. h PLA images using Ac.-lysine and C/EBPβ antibodies to analyze lung samples from BLM-treated with control or C646. Arrowheads indicate positive signals. Scale bar, 10 μm. i The mean intensity of the PLA-positive signal was quantified using ZEN 3.0 software. n = 5 per group. j Representative MTS-stained lung sections from BLM-treated mice treated with control or TCID (0.15 or 0.75 mg/kg). k Collagen deposition was quantified in MTS-stained lung samples from BLM-treated mice treated with control or TCID. n = 3–5 per group. l Colocalization of p300 (green), UCHL3 (red), and SPC (gray) by IF staining in the indicated mouse lung samples. Scale bar, 50 μm. n = 3. m The graph shows the weighted colocalized coefficiency. Error bars, mean ± s.e.m. **P < 0.01, ***P < 0.001 and ****P < 0.0001, one-way ANOVA followed by Tukey’s test.